On May 28, 2024, Cytokinetics, Incorporated closed the transaction. The shares issued to investor were issued in reliance upon the exemption from registration pursuant to Section 4(a)(2) under the Securities Act in a transaction not involving a public offering of such shares.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
53.9 USD | +0.71% |
|
+2.12% | -35.44% |
06-24 | JPMorgan Cuts Price Target on Cytokinetics to $65 From $77, Maintains Overweight Rating | MT |
06-17 | Cytokinetics Insider Sold Shares Worth $262,750, According to a Recent SEC Filing | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-35.44% | 6.26B | |
+16.73% | 123B | |
+21.13% | 115B | |
+18.05% | 25.85B | |
-17.94% | 20.9B | |
-16.24% | 16.52B | |
-11.76% | 16.77B | |
-44.45% | 15.56B | |
+69.92% | 15.49B | |
+1.41% | 13.45B |
- Stock Market
- Equities
- CYTK Stock
- News Cytokinetics, Incorporated
- Cytokinetics, Incorporated announced that it has received $49.999992 million in funding from Royalty Pharma Development Funding, LLC